View Financial HealtheXoZymes 배당 및 자사주 매입배당 기준 점검 0/6eXoZymes 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-17.3%자사주 매입 수익률총 주주 수익률-17.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 10eXoZymes, Inc. has filed a Follow-on Equity Offering.eXoZymes, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock공시 • Mar 26eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026New Risk • Dec 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$96.4m market cap).분석 기사 • Nov 13We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Jul 30We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...공시 • Jun 30+ 1 more updateeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value IndexeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value Index공시 • Jun 23eXoZymes, Inc., Annual General Meeting, Jul 25, 2025eXoZymes, Inc., Annual General Meeting, Jul 25, 2025.New Risk • Jun 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$76.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$76.6m market cap).공시 • Apr 11eXoZymes Inc. Announces Its Latest Initiative BioClickeXoZymes Inc. announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry concept of Click Chemistry, often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs. Critically, the BioClick tools also introduce new high-throughput screening capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction - greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug.공시 • Apr 03eXoZymes Inc. Appoints Damien Perriman as Chief Commercial OfficereXoZymes Inc. announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.New Risk • Mar 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$96.5m market cap).공시 • Mar 27eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025공시 • Feb 23eXoZymes, Inc. Announces Management ChangesOn February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors of eXoZymes Inc. as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company. On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation. There is no current arrangement in place for compensation to Mr. Rayo as a director. The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.New Risk • Jan 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Market cap is less than US$100m (US$99.7m market cap).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 EXOZ 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: EXOZ 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장eXoZymes 배당 수익률 vs 시장EXOZ의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (EXOZ)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (EXOZ) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 EXOZ 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 EXOZ 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 EXOZ 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: EXOZ 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 08:18종가2026/05/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스eXoZymes, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 10eXoZymes, Inc. has filed a Follow-on Equity Offering.eXoZymes, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
공시 • Mar 26eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026
New Risk • Dec 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$96.4m market cap).
분석 기사 • Nov 13We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Jul 30We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
공시 • Jun 30+ 1 more updateeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value IndexeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value Index
공시 • Jun 23eXoZymes, Inc., Annual General Meeting, Jul 25, 2025eXoZymes, Inc., Annual General Meeting, Jul 25, 2025.
New Risk • Jun 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$76.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$76.6m market cap).
공시 • Apr 11eXoZymes Inc. Announces Its Latest Initiative BioClickeXoZymes Inc. announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry concept of Click Chemistry, often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs. Critically, the BioClick tools also introduce new high-throughput screening capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction - greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug.
공시 • Apr 03eXoZymes Inc. Appoints Damien Perriman as Chief Commercial OfficereXoZymes Inc. announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.
New Risk • Mar 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$96.5m market cap).
공시 • Mar 27eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025
공시 • Feb 23eXoZymes, Inc. Announces Management ChangesOn February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors of eXoZymes Inc. as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company. On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation. There is no current arrangement in place for compensation to Mr. Rayo as a director. The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.
New Risk • Jan 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Market cap is less than US$100m (US$99.7m market cap).